APO Research
Talk to an analyst

APO RESEARCH · REPORT

Genetic COPD

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Genetic COPD Market Analysis and Forecast 2026-2032

2 January 2026203 pages

Choose your research edition.

Industry ResearchGenetic COPD Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal Genetic COPD Industry Growth and Trends Forecast to 2032120 pages · $3,450 USDMarket StructureGlobal Genetic COPD Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Genetic COPD Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Genetic COPD Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global Genetic COPD market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Genetic COPD is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Genetic COPD is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Genetic COPD is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Genetic COPD is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Genetic COPD include Takeda, Pfizer, GlaxoSmithKline, Baxter, AstraZeneca, Vertex Pharmaceuticals, Teva Pharmaceutical Industries, ProMetic Life Sciences and ProBioGen, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Genetic COPD, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Genetic COPD, also provides the revenue of main regions and countries. Of the upcoming market potential for Genetic COPD, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Genetic COPD revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Genetic COPD market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Genetic COPD revenue, projected growth trends, production technology, application and end-user industry.

Genetic COPD Segment by Company

Takeda

Pfizer

GlaxoSmithKline

Baxter

AstraZeneca

Vertex Pharmaceuticals

Teva Pharmaceutical Industries

ProMetic Life Sciences

ProBioGen

LFB Biomedicaments

Kedrion Group

Kamada Ltd

Grifols

CSL Behring

Chiesi Pharmaceuticals

Boehringer Ingelheim

Biogen

Baxalta

Arrowhead Research Corporation

Abeona Therapeutics

Genetic COPD Segment by Type

Augmentation Therapy

Cystic Fibrosis(CF)

Non-CF Bronchiectasis(NCFB)

Other

Genetic COPD Segment by Application

Specialty Clinics

Hospitals

Pharmacies

Others

Genetic COPD Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Genetic COPD market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Genetic COPD and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Genetic COPD.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Genetic COPD in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Genetic COPD company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Genetic COPD revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Genetic COPD Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Augmentation Therapy Major Player Table 3. Cystic Fibrosis(CF) Major Player Table 4. Non-CF Bronchiectasis(NCFB) Major Player Table 5. Other Major Player Table 6. Global Genetic COPD Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Specialty Clinics Major Player Table 8. Hospitals Major Player Table 9. Pharmacies Major Player Table 10. Others Major Player Table 11. Genetic COPD Industry Trends Table 12. Genetic COPD Industry Drivers Table 13. Genetic COPD Industry Opportunities and Challenges Table 14. Genetic COPD Industry Restraints Table 15. Global Genetic COPD Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Genetic COPD Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Genetic COPD Market Share by Region (2021-2026) Table 18. Global Genetic COPD Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Genetic COPD Market Share by Region (2027-2032) Table 20. Global Genetic COPD Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Genetic COPD Revenue Market Share by Players (2021-2026) Table 22. Global Genetic COPD Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Genetic COPD Key Players Headquarters & Area Served Table 24. Global Genetic COPD Players, Product Type & Application Table 25. Global Genetic COPD Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Genetic COPD by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Genetic COPD Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Genetic COPD Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Genetic COPD Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Genetic COPD Revenue Market Share by Type (2021-2026) Table 32. Global Genetic COPD Revenue Market Share by Type (2027-2032) Table 33. Global Genetic COPD Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Genetic COPD Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Genetic COPD Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Genetic COPD Revenue Market Share by Application (2021-2026) Table 37. Global Genetic COPD Revenue Market Share by Application (2027-2032) Table 38. Takeda Company Information Table 39. Takeda Business Overview Table 40. Takeda Genetic COPD Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Takeda Genetic COPD Product Portfolio Table 42. Takeda Recent Development Table 43. Pfizer Company Information Table 44. Pfizer Business Overview Table 45. Pfizer Genetic COPD Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Pfizer Genetic COPD Product Portfolio Table 47. Pfizer Recent Development Table 48. GlaxoSmithKline Company Information Table 49. GlaxoSmithKline Business Overview Table 50. GlaxoSmithKline Genetic COPD Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. GlaxoSmithKline Genetic COPD Product Portfolio Table 52. GlaxoSmithKline Recent Development Table 53. Baxter Company Information Table 54. Baxter Business Overview Table 55. Baxter Genetic COPD Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Baxter Genetic COPD Product Portfolio Table 57. Baxter Recent Development Table 58. AstraZeneca Company Information Table 59. AstraZeneca Business Overview Table 60. AstraZeneca Genetic COPD Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. AstraZeneca Genetic COPD Product Portfolio Table 62. AstraZeneca Recent Development Table 63. Vertex Pharmaceuticals Company Information Table 64. Vertex Pharmaceuticals Business Overview Table 65. Vertex Pharmaceuticals Genetic COPD Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Vertex Pharmaceuticals Genetic COPD Product Portfolio Table 67. Vertex Pharmaceuticals Recent Development Table 68. Teva Pharmaceutical Industries Company Information Table 69. Teva Pharmaceutical Industries Business Overview Table 70. Teva Pharmaceutical Industries Genetic COPD Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Teva Pharmaceutical Industries Genetic COPD Product Portfolio Table 72. Teva Pharmaceutical Industries Recent Development Table 73. ProMetic Life Sciences Company Information Table 74. ProMetic Life Sciences Business Overview Table 75. ProMetic Life Sciences Genetic COPD Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. ProMetic Life Sciences Genetic COPD Product Portfolio Table 77. ProMetic Life Sciences Recent Development Table 78. ProBioGen Company Information Table 79. ProBioGen Business Overview Table 80. ProBioGen Genetic COPD Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. ProBioGen Genetic COPD Product Portfolio Table 82. ProBioGen Recent Development Table 83. LFB Biomedicaments Company Information Table 84. LFB Biomedicaments Business Overview Table 85. LFB Biomedicaments Genetic COPD Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. LFB Biomedicaments Genetic COPD Product Portfolio Table 87. LFB Biomedicaments Recent Development Table 88. Kedrion Group Company Information Table 89. Kedrion Group Business Overview Table 90. Kedrion Group Genetic COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Kedrion Group Genetic COPD Product Portfolio Table 92. Kedrion Group Recent Development Table 93. Kamada Ltd Company Information Table 94. Kamada Ltd Business Overview Table 95. Kamada Ltd Genetic COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Kamada Ltd Genetic COPD Product Portfolio Table 97. Kamada Ltd Recent Development Table 98. Grifols Company Information Table 99. Grifols Business Overview Table 100. Grifols Genetic COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Grifols Genetic COPD Product Portfolio Table 102. Grifols Recent Development Table 103. CSL Behring Company Information Table 104. CSL Behring Business Overview Table 105. CSL Behring Genetic COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. CSL Behring Genetic COPD Product Portfolio Table 107. CSL Behring Recent Development Table 108. Chiesi Pharmaceuticals Company Information Table 109. Chiesi Pharmaceuticals Business Overview Table 110. Chiesi Pharmaceuticals Genetic COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Chiesi Pharmaceuticals Genetic COPD Product Portfolio Table 112. Chiesi Pharmaceuticals Recent Development Table 113. Boehringer Ingelheim Company Information Table 114. Boehringer Ingelheim Business Overview Table 115. Boehringer Ingelheim Genetic COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Boehringer Ingelheim Genetic COPD Product Portfolio Table 117. Boehringer Ingelheim Recent Development Table 118. Biogen Company Information Table 119. Biogen Business Overview Table 120. Biogen Genetic COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Biogen Genetic COPD Product Portfolio Table 122. Biogen Recent Development Table 123. Baxalta Company Information Table 124. Baxalta Business Overview Table 125. Baxalta Genetic COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Baxalta Genetic COPD Product Portfolio Table 127. Baxalta Recent Development Table 128. Arrowhead Research Corporation Company Information Table 129. Arrowhead Research Corporation Business Overview Table 130. Arrowhead Research Corporation Genetic COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Arrowhead Research Corporation Genetic COPD Product Portfolio Table 132. Arrowhead Research Corporation Recent Development Table 133. Abeona Therapeutics Company Information Table 134. Abeona Therapeutics Business Overview Table 135. Abeona Therapeutics Genetic COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Abeona Therapeutics Genetic COPD Product Portfolio Table 137. Abeona Therapeutics Recent Development Table 138. North America Genetic COPD Revenue by Type (2021-2026) & (US$ Million) Table 139. North America Genetic COPD Revenue by Type (2027-2032) & (US$ Million) Table 140. North America Genetic COPD Revenue by Application (2021-2026) & (US$ Million) Table 141. North America Genetic COPD Revenue by Application (2027-2032) & (US$ Million) Table 142. North America Genetic COPD Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 143. North America Genetic COPD Revenue by Country (2021-2026) & (US$ Million) Table 144. North America Genetic COPD Revenue by Country (US$ Million) & (2027-2032) Table 145. Europe Genetic COPD Revenue by Type (2021-2026) & (US$ Million) Table 146. Europe Genetic COPD Revenue by Type (2027-2032) & (US$ Million) Table 147. Europe Genetic COPD Revenue by Application (2021-2026) & (US$ Million) Table 148. Europe Genetic COPD Revenue by Application (2027-2032) & (US$ Million) Table 149. Europe Genetic COPD Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 150. Europe Genetic COPD Revenue by Country (2021-2026) & (US$ Million) Table 151. Europe Genetic COPD Revenue by Country (US$ Million) & (2027-2032) Table 152. China Genetic COPD Revenue by Type (2021-2026) & (US$ Million) Table 153. China Genetic COPD Revenue by Type (2027-2032) & (US$ Million) Table 154. China Genetic COPD Revenue by Application (2021-2026) & (US$ Million) Table 155. China Genetic COPD Revenue by Application (2027-2032) & (US$ Million) Table 156. Asia Genetic COPD Revenue by Type (2021-2026) & (US$ Million) Table 157. Asia Genetic COPD Revenue by Type (2027-2032) & (US$ Million) Table 158. Asia Genetic COPD Revenue by Application (2021-2026) & (US$ Million) Table 159. Asia Genetic COPD Revenue by Application (2027-2032) & (US$ Million) Table 160. Asia Genetic COPD Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 161. Asia Genetic COPD Revenue by Region (US$ Million) & (2021-2026) Table 162. Asia Genetic COPD Revenue by Region (US$ Million) & (2027-2032) Table 163. SAMEA Genetic COPD Revenue by Type (2021-2026) & (US$ Million) Table 164. SAMEA Genetic COPD Revenue by Type (2027-2032) & (US$ Million) Table 165. SAMEA Genetic COPD Revenue by Application (2021-2026) & (US$ Million) Table 166. SAMEA Genetic COPD Revenue by Application (2027-2032) & (US$ Million) Table 167. SAMEA Genetic COPD Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 168. SAMEA Genetic COPD Revenue by Country (2021-2026) & (US$ Million) Table 169. SAMEA Genetic COPD Revenue by Country (US$ Million) & (2027-2032) Table 170. Research Programs/Design for This Report Table 171. Authors List of This Report Table 172. Secondary Sources Table 173. Primary Sources List of Figures Figure 1. Genetic COPD Image Figure 2. Global Genetic COPD Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Genetic COPD Market Size Share 2021 VS 2025 VS 2032 Figure 4. Augmentation Therapy Image Figure 5. Cystic Fibrosis(CF) Image Figure 6. Non-CF Bronchiectasis(NCFB) Image Figure 7. Other Image Figure 8. Global Genetic COPD Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Genetic COPD Market Size Share 2021 VS 2025 VS 2032 Figure 10. Specialty Clinics Image Figure 11. Hospitals Image Figure 12. Pharmacies Image Figure 13. Others Image Figure 14. Global Genetic COPD Market Size (US$ Million) & (2021-2032) Figure 15. Global Genetic COPD Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Genetic COPD Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Genetic COPD Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Genetic COPD Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Genetic COPD Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Genetic COPD Revenue Market Share by Type (2021-2032) Figure 22. Global Genetic COPD Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Genetic COPD Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Genetic COPD Revenue Market Share by Application (2021-2032) Figure 25. North America Genetic COPD Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Genetic COPD Revenue Share by Type (2021-2032) Figure 27. North America Genetic COPD Revenue Share by Application (2021-2032) Figure 28. North America Genetic COPD Revenue Share by Country (2021-2032) Figure 29. United States Genetic COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Genetic COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Genetic COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Genetic COPD Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Genetic COPD Revenue Share by Type (2021-2032) Figure 34. Europe Genetic COPD Revenue Share by Application (2021-2032) Figure 35. Europe Genetic COPD Revenue Share by Country (2021-2032) Figure 36. Germany Genetic COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Genetic COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Genetic COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Genetic COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Genetic COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Genetic COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Genetic COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Genetic COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Genetic COPD Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Genetic COPD Revenue Share by Type (2021-2032) Figure 46. China Genetic COPD Revenue Share by Application (2021-2032) Figure 47. Asia Genetic COPD Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Genetic COPD Revenue Share by Type (2021-2032) Figure 49. Asia Genetic COPD Revenue Share by Application (2021-2032) Figure 50. Asia Genetic COPD Revenue Share by Region (2021-2032) Figure 51. Japan Genetic COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Genetic COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Genetic COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Genetic COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Genetic COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Genetic COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Genetic COPD Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Genetic COPD Revenue Share by Type (2021-2032) Figure 59. SAMEA Genetic COPD Revenue Share by Application (2021-2032) Figure 60. SAMEA Genetic COPD Revenue Share by Country (2021-2032) Figure 61. Brazil Genetic COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Genetic COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Genetic COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Genetic COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Genetic COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Genetic COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Genetic COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Genetic COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Genetic COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Genetic COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Genetic COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Augmentation Therapy
  • Cystic Fibrosis(CF)
  • Non-CF Bronchiectasis(NCFB)
  • Other
Applications
  • Specialty Clinics
  • Hospitals
  • Pharmacies
  • Others
Companies covered
  • Takeda
  • Pfizer
  • GlaxoSmithKline
  • Baxter
  • AstraZeneca
  • Vertex Pharmaceuticals
  • Teva Pharmaceutical Industries
  • ProMetic Life Sciences
  • ProBioGen
  • LFB Biomedicaments
  • Kedrion Group
  • Kamada Ltd
  • Grifols
  • CSL Behring
  • Chiesi Pharmaceuticals
  • Boehringer Ingelheim
  • Biogen
  • Baxalta
  • Arrowhead Research Corporation
  • Abeona Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Genetic COPD Market by Type
  3. 1.2.1 Global Genetic COPD Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Augmentation Therapy
  5. 1.2.3 Cystic Fibrosis(CF)
  6. 1.2.4 Non-CF Bronchiectasis(NCFB)
  7. 1.2.5 Other
  8. 1.3 Genetic COPD Market by Application
  9. 1.3.1 Global Genetic COPD Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Specialty Clinics
  11. 1.3.3 Hospitals
  12. 1.3.4 Pharmacies
  13. 1.3.5 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Genetic COPD Market Dynamics
  1. 2.1 Genetic COPD Industry Trends
  2. 2.2 Genetic COPD Industry Drivers
  3. 2.3 Genetic COPD Industry Opportunities and Challenges
  4. 2.4 Genetic COPD Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Genetic COPD Market Perspective (2021-2032)
  2. 3.2 Global Genetic COPD Growth Trends by Region
  3. 3.2.1 Global Genetic COPD Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Genetic COPD Market Size by Region (2021-2026)
  5. 3.2.3 Global Genetic COPD Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Genetic COPD Revenue by Players
  2. 4.1.1 Global Genetic COPD Revenue by Players (2021-2026)
  3. 4.1.2 Global Genetic COPD Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Genetic COPD Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Genetic COPD Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Genetic COPD Key Players Headquarters & Area Served
  7. 4.4 Global Genetic COPD Players, Product Type & Application
  8. 4.5 Global Genetic COPD Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Genetic COPD Market CR5 and HHI
  11. 4.6.3 2025 Genetic COPD Tier 1, Tier 2, and Tier 3
5 Genetic COPD Market Size by Type
  1. 5.1 Global Genetic COPD Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Genetic COPD Revenue by Type (2021-2032)
  3. 5.3 Global Genetic COPD Revenue Market Share by Type (2021-2032)
6 Genetic COPD Market Size by Application
  1. 6.1 Global Genetic COPD Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Genetic COPD Revenue by Application (2021-2032)
  3. 6.3 Global Genetic COPD Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Takeda
  2. 7.1.1 Takeda Company Information
  3. 7.1.2 Takeda Business Overview
  4. 7.1.3 Takeda Genetic COPD Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Takeda Genetic COPD Product Portfolio
  6. 7.1.5 Takeda Recent Developments
  7. 7.2 Pfizer
  8. 7.2.1 Pfizer Company Information
  9. 7.2.2 Pfizer Business Overview
  10. 7.2.3 Pfizer Genetic COPD Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Pfizer Genetic COPD Product Portfolio
  12. 7.2.5 Pfizer Recent Developments
  13. 7.3 GlaxoSmithKline
  14. 7.3.1 GlaxoSmithKline Company Information
  15. 7.3.2 GlaxoSmithKline Business Overview
  16. 7.3.3 GlaxoSmithKline Genetic COPD Revenue and Gross Margin (2021-2026)
  17. 7.3.4 GlaxoSmithKline Genetic COPD Product Portfolio
  18. 7.3.5 GlaxoSmithKline Recent Developments
  19. 7.4 Baxter
  20. 7.4.1 Baxter Company Information
  21. 7.4.2 Baxter Business Overview
  22. 7.4.3 Baxter Genetic COPD Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Baxter Genetic COPD Product Portfolio
  24. 7.4.5 Baxter Recent Developments
  25. 7.5 AstraZeneca
  26. 7.5.1 AstraZeneca Company Information
  27. 7.5.2 AstraZeneca Business Overview
  28. 7.5.3 AstraZeneca Genetic COPD Revenue and Gross Margin (2021-2026)
  29. 7.5.4 AstraZeneca Genetic COPD Product Portfolio
  30. 7.5.5 AstraZeneca Recent Developments
  31. 7.6 Vertex Pharmaceuticals
  32. 7.6.1 Vertex Pharmaceuticals Company Information
  33. 7.6.2 Vertex Pharmaceuticals Business Overview
  34. 7.6.3 Vertex Pharmaceuticals Genetic COPD Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Vertex Pharmaceuticals Genetic COPD Product Portfolio
  36. 7.6.5 Vertex Pharmaceuticals Recent Developments
  37. 7.7 Teva Pharmaceutical Industries
  38. 7.7.1 Teva Pharmaceutical Industries Company Information
  39. 7.7.2 Teva Pharmaceutical Industries Business Overview
  40. 7.7.3 Teva Pharmaceutical Industries Genetic COPD Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Teva Pharmaceutical Industries Genetic COPD Product Portfolio
  42. 7.7.5 Teva Pharmaceutical Industries Recent Developments
  43. 7.8 ProMetic Life Sciences
  44. 7.8.1 ProMetic Life Sciences Company Information
  45. 7.8.2 ProMetic Life Sciences Business Overview
  46. 7.8.3 ProMetic Life Sciences Genetic COPD Revenue and Gross Margin (2021-2026)
  47. 7.8.4 ProMetic Life Sciences Genetic COPD Product Portfolio
  48. 7.8.5 ProMetic Life Sciences Recent Developments
  49. 7.9 ProBioGen
  50. 7.9.1 ProBioGen Company Information
  51. 7.9.2 ProBioGen Business Overview
  52. 7.9.3 ProBioGen Genetic COPD Revenue and Gross Margin (2021-2026)
  53. 7.9.4 ProBioGen Genetic COPD Product Portfolio
  54. 7.9.5 ProBioGen Recent Developments
  55. 7.10 LFB Biomedicaments
  56. 7.10.1 LFB Biomedicaments Company Information
  57. 7.10.2 LFB Biomedicaments Business Overview
  58. 7.10.3 LFB Biomedicaments Genetic COPD Revenue and Gross Margin (2021-2026)
  59. 7.10.4 LFB Biomedicaments Genetic COPD Product Portfolio
  60. 7.10.5 LFB Biomedicaments Recent Developments
  61. 7.11 Kedrion Group
  62. 7.11.1 Kedrion Group Company Information
  63. 7.11.2 Kedrion Group Business Overview
  64. 7.11.3 Kedrion Group Genetic COPD Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Kedrion Group Genetic COPD Product Portfolio
  66. 7.11.5 Kedrion Group Recent Developments
  67. 7.12 Kamada Ltd
  68. 7.12.1 Kamada Ltd Company Information
  69. 7.12.2 Kamada Ltd Business Overview
  70. 7.12.3 Kamada Ltd Genetic COPD Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Kamada Ltd Genetic COPD Product Portfolio
  72. 7.12.5 Kamada Ltd Recent Developments
  73. 7.13 Grifols
  74. 7.13.1 Grifols Company Information
  75. 7.13.2 Grifols Business Overview
  76. 7.13.3 Grifols Genetic COPD Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Grifols Genetic COPD Product Portfolio
  78. 7.13.5 Grifols Recent Developments
  79. 7.14 CSL Behring
  80. 7.14.1 CSL Behring Company Information
  81. 7.14.2 CSL Behring Business Overview
  82. 7.14.3 CSL Behring Genetic COPD Revenue and Gross Margin (2021-2026)
  83. 7.14.4 CSL Behring Genetic COPD Product Portfolio
  84. 7.14.5 CSL Behring Recent Developments
  85. 7.15 Chiesi Pharmaceuticals
  86. 7.15.1 Chiesi Pharmaceuticals Company Information
  87. 7.15.2 Chiesi Pharmaceuticals Business Overview
  88. 7.15.3 Chiesi Pharmaceuticals Genetic COPD Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Chiesi Pharmaceuticals Genetic COPD Product Portfolio
  90. 7.15.5 Chiesi Pharmaceuticals Recent Developments
  91. 7.16 Boehringer Ingelheim
  92. 7.16.1 Boehringer Ingelheim Company Information
  93. 7.16.2 Boehringer Ingelheim Business Overview
  94. 7.16.3 Boehringer Ingelheim Genetic COPD Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Boehringer Ingelheim Genetic COPD Product Portfolio
  96. 7.16.5 Boehringer Ingelheim Recent Developments
  97. 7.17 Biogen
  98. 7.17.1 Biogen Company Information
  99. 7.17.2 Biogen Business Overview
  100. 7.17.3 Biogen Genetic COPD Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Biogen Genetic COPD Product Portfolio
  102. 7.17.5 Biogen Recent Developments
  103. 7.18 Baxalta
  104. 7.18.1 Baxalta Company Information
  105. 7.18.2 Baxalta Business Overview
  106. 7.18.3 Baxalta Genetic COPD Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Baxalta Genetic COPD Product Portfolio
  108. 7.18.5 Baxalta Recent Developments
  109. 7.19 Arrowhead Research Corporation
  110. 7.19.1 Arrowhead Research Corporation Company Information
  111. 7.19.2 Arrowhead Research Corporation Business Overview
  112. 7.19.3 Arrowhead Research Corporation Genetic COPD Revenue and Gross Margin (2021-2026)
  113. 7.19.4 Arrowhead Research Corporation Genetic COPD Product Portfolio
  114. 7.19.5 Arrowhead Research Corporation Recent Developments
  115. 7.20 Abeona Therapeutics
  116. 7.20.1 Abeona Therapeutics Company Information
  117. 7.20.2 Abeona Therapeutics Business Overview
  118. 7.20.3 Abeona Therapeutics Genetic COPD Revenue and Gross Margin (2021-2026)
  119. 7.20.4 Abeona Therapeutics Genetic COPD Product Portfolio
  120. 7.20.5 Abeona Therapeutics Recent Developments
8 North America
  1. 8.1 North America Genetic COPD Revenue (2021-2032)
  2. 8.2 North America Genetic COPD Revenue by Type (2021-2032)
  3. 8.2.1 North America Genetic COPD Revenue by Type (2021-2026)
  4. 8.2.2 North America Genetic COPD Revenue by Type (2027-2032)
  5. 8.3 North America Genetic COPD Revenue Share by Type (2021-2032)
  6. 8.4 North America Genetic COPD Revenue by Application (2021-2032)
  7. 8.4.1 North America Genetic COPD Revenue by Application (2021-2026)
  8. 8.4.2 North America Genetic COPD Revenue by Application (2027-2032)
  9. 8.5 North America Genetic COPD Revenue Share by Application (2021-2032)
  10. 8.6 North America Genetic COPD Revenue by Country
  11. 8.6.1 North America Genetic COPD Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Genetic COPD Revenue by Country (2021-2026)
  13. 8.6.3 North America Genetic COPD Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Genetic COPD Revenue (2021-2032)
  2. 9.2 Europe Genetic COPD Revenue by Type (2021-2032)
  3. 9.2.1 Europe Genetic COPD Revenue by Type (2021-2026)
  4. 9.2.2 Europe Genetic COPD Revenue by Type (2027-2032)
  5. 9.3 Europe Genetic COPD Revenue Share by Type (2021-2032)
  6. 9.4 Europe Genetic COPD Revenue by Application (2021-2032)
  7. 9.4.1 Europe Genetic COPD Revenue by Application (2021-2026)
  8. 9.4.2 Europe Genetic COPD Revenue by Application (2027-2032)
  9. 9.5 Europe Genetic COPD Revenue Share by Application (2021-2032)
  10. 9.6 Europe Genetic COPD Revenue by Country
  11. 9.6.1 Europe Genetic COPD Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Genetic COPD Revenue by Country (2021-2026)
  13. 9.6.3 Europe Genetic COPD Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Genetic COPD Revenue (2021-2032)
  2. 10.2 China Genetic COPD Revenue by Type (2021-2032)
  3. 10.2.1 China Genetic COPD Revenue by Type (2021-2026)
  4. 10.2.2 China Genetic COPD Revenue by Type (2027-2032)
  5. 10.3 China Genetic COPD Revenue Share by Type (2021-2032)
  6. 10.4 China Genetic COPD Revenue by Application (2021-2032)
  7. 10.4.1 China Genetic COPD Revenue by Application (2021-2026)
  8. 10.4.2 China Genetic COPD Revenue by Application (2027-2032)
  9. 10.5 China Genetic COPD Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Genetic COPD Revenue (2021-2032)
  2. 11.2 Asia Genetic COPD Revenue by Type (2021-2032)
  3. 11.2.1 Asia Genetic COPD Revenue by Type (2021-2026)
  4. 11.2.2 Asia Genetic COPD Revenue by Type (2027-2032)
  5. 11.3 Asia Genetic COPD Revenue Share by Type (2021-2032)
  6. 11.4 Asia Genetic COPD Revenue by Application (2021-2032)
  7. 11.4.1 Asia Genetic COPD Revenue by Application (2021-2026)
  8. 11.4.2 Asia Genetic COPD Revenue by Application (2027-2032)
  9. 11.5 Asia Genetic COPD Revenue Share by Application (2021-2032)
  10. 11.6 Asia Genetic COPD Revenue by Country
  11. 11.6.1 Asia Genetic COPD Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Genetic COPD Revenue by Country (2021-2026)
  13. 11.6.3 Asia Genetic COPD Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Genetic COPD Revenue (2021-2032)
  2. 12.2 SAMEA Genetic COPD Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Genetic COPD Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Genetic COPD Revenue by Type (2027-2032)
  5. 12.3 SAMEA Genetic COPD Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Genetic COPD Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Genetic COPD Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Genetic COPD Revenue by Application (2027-2032)
  9. 12.5 SAMEA Genetic COPD Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Genetic COPD Revenue by Country
  11. 12.6.1 SAMEA Genetic COPD Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Genetic COPD Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Genetic COPD Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst